ImageneBio (NASDAQ:IMA) Stock Rating Upgraded by HC Wainwright

ImageneBio (NASDAQ:IMA) was upgraded by analysts at HC Wainwright to a “strong-buy” rating in a research report issued on Friday,Zacks.com reports.

Several other research firms also recently issued reports on IMA. Wedbush reaffirmed an “underperform” rating on shares of ImageneBio in a report on Monday, May 11th. Wall Street Zen cut ImageneBio from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 17th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, ImageneBio has an average rating of “Hold” and a consensus price target of $29.00.

ImageneBio Trading Down 1.8%

IMA opened at $5.51 on Friday. ImageneBio has a 1-year low of $3.94 and a 1-year high of $14.34. The stock has a market capitalization of $62.54 million, a PE ratio of -1.20 and a beta of 0.76. The firm has a 50-day moving average price of $5.79 and a two-hundred day moving average price of $5.86.

ImageneBio (NASDAQ:IMA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.27. On average, research analysts predict that ImageneBio will post -3.07 EPS for the current year.

Institutional Investors Weigh In On ImageneBio

Several institutional investors have recently modified their holdings of the business. Blue Owl Capital Holdings LP bought a new stake in shares of ImageneBio during the second quarter worth approximately $5,414,000. Deep Track Capital LP bought a new position in ImageneBio in the third quarter valued at approximately $7,160,000. Cable Car Capital LP bought a new position in ImageneBio in the second quarter valued at approximately $4,611,000. Trails Edge Capital Partners LP acquired a new stake in ImageneBio during the 2nd quarter worth $1,663,824,000. Finally, Vanguard Group Inc. acquired a new stake in ImageneBio during the 3rd quarter worth $1,902,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.